Literature DB >> 26351474

Comparison of Serum Autoantibodies to Desmogleins I, III in Patients with Oral Lichen Planus and Healthy Controls.

Narges Gholizadeh1, Hossein Khoini Poorfar2, Ali TaghaviZenouz3, Masoumeh Vatandoost4, Masoumeh Mehdipour5.   

Abstract

BACKGROUND &
OBJECTIVE: Lichen planus is a mucocutaneous disease which is relatively common and in 30-70% of patients, mucosal lesions can be seen and known as a precancerous lesion but its etiology is not completely understood. Desmogleins I and III are the main desmosomal transmembrane proteins. These proteins have been identified as the autoantigen of the autoimmune disease. The aim of this study was evaluation of serum autoantibodies against desmogleins Ι, ΙΙΙ in oral lichen planus .
METHODS: We attempted to determine the etiology of this disease with evaluation of these serum factors. Thirty-five patients with oral lichen planus and 35 healthy controls were recruited and tested for serum autoantibodies against desmogleins Ι, ΙΙΙ and indirect immunofluorescence also performed. Data were analyzed by statistical-analytical methods (Independent sample t -test) with using the SPSS.15 software.
RESULTS: Serum autoantibody against desmoglein Ι had no significant difference in the two groups ( P =0.31 ) but significant increase in serum autoantibody to desmoglein ΙΙΙ was found in patients with oral lichen planus ( P =0.00) .
CONCLUSION: It seems that autoantibody against desmoglein III has a significant role in the pathogenesis of oral lichen planus.

Entities:  

Keywords:  III -Serum Level; Lichen Planus- Desmogleins I

Year:  2015        PMID: 26351474      PMCID: PMC4539751     

Source DB:  PubMed          Journal:  Iran J Pathol        ISSN: 1735-5303


  8 in total

Review 1.  Lichen planus and lichenoid reactions of the oral mucosa.

Authors:  Bethanee J Schlosser
Journal:  Dermatol Ther       Date:  2010 May-Jun       Impact factor: 2.851

Review 2.  Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation.

Authors:  Sumairi B Ismail; Satish K S Kumar; Rosnah B Zain
Journal:  J Oral Sci       Date:  2007-06       Impact factor: 1.556

3.  The Declaration of Helsinki and public health.

Authors:  John R Williams
Journal:  Bull World Health Organ       Date:  2008-08       Impact factor: 9.408

4.  Oral lichen planus is not associated with IgG circulating antibodies to epithelial antigens.

Authors:  M Ingafou; G Lodi; I Olsen; S R Porter
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  1997-08

Review 5.  Immunopathogenesis of oral lichen planus and recurrent aphthous stomatitis.

Authors:  L R Eversole
Journal:  Semin Cutan Med Surg       Date:  1997-12

6.  Serum autoantibodies to desmogleins 1 and 3 in patients with oral lichen planus.

Authors:  Josip Lukac; Suzana Brozović; Vanja Vucicević-Boras; Marinka Mravak-Stipetić; Branko Malenica; Zvonko Kusić
Journal:  Croat Med J       Date:  2006-02       Impact factor: 1.351

7.  Demographic and clinical profile of oral lichen planus: A retrospective study.

Authors:  Anita D Munde; Ravindra R Karle; Pranali K Wankhede; Safia S Shaikh; Meena Kulkurni
Journal:  Contemp Clin Dent       Date:  2013-04

8.  Desmoglein 2 is less important than desmoglein 3 for keratinocyte cohesion.

Authors:  Eva Hartlieb; Bettina Kempf; Miriam Partilla; Balázs Vigh; Volker Spindler; Jens Waschke
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

  8 in total
  2 in total

1.  Association of MAPK and its regulatory miRNAs (603, 4301, 8485, and 4731) with the malignant transformation of oral lichen planus.

Authors:  Narges Gholizadeh; Amirnader Emami Razavi; Hadiseh Mohammadpour; Fatemeh Tavakol; Nafiseh Sheykhbahaei
Journal:  Mol Biol Rep       Date:  2019-12-11       Impact factor: 2.316

2.  Keratinocyte Binding Assay Identifies Anti-Desmosomal Pemphigus Antibodies Where Other Tests Are Negative.

Authors:  Federica Giurdanella; Albertine M Nijenhuis; Gilles F H Diercks; Marcel F Jonkman; Hendri H Pas
Journal:  Front Immunol       Date:  2018-04-24       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.